170 related articles for article (PubMed ID: 38372904)
1. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Giancotti FG; Filatov A; Derman A; Hochman T; Goldberg JD; Vega E; Wisoff JH; Golfinos JG; Merkelson A; Roland JT; Allen JC
Neuro Oncol; 2014 Jan; 16(2):292-7. PubMed ID: 24311643
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma.
Zhao F; Li SW; Zhang S; Li P; Zhao C; Zhao XB; Wang CH; Zhang J; Wang B; Liu PN
J Neurosurg; 2023 Jun; 138(6):1680-1687. PubMed ID: 36272122
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
8. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.
Jordan JT; Orr CC; Thalheimer RD; Cambillo JV; Beauchamp RL; Shaikh G; Muzikansky A; Stemmer-Rachamimov A; Giovannini M; Kalamarides M; Barker FG; Ramesh V; Plotkin SR
Neurooncol Adv; 2023; 5(1):vdad041. PubMed ID: 37215956
[TBL] [Abstract][Full Text] [Related]
10. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
11. Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
Karajannis MA; Mauguen A; Maloku E; Xu Q; Dunbar EM; Plotkin SR; Yaffee A; Wang S; Roland JT; Sen C; Placantonakis DG; Golfinos JG; Allen JC; Vitanza NA; Chiriboga LA; Schneider RJ; Deng J; Neubert TA; Goldberg JD; Zagzag D; Giancotti FG; Blakeley JO
Mol Cancer Ther; 2021 Sep; 20(9):1584-1591. PubMed ID: 34224367
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
13. The comparable tumour microenvironment in sporadic and
Gregory GE; Jones AP; Haley MJ; Hoyle C; Zeef LAH; Lin IH; Coope DJ; King AT; Evans DG; Paszek P; Couper KN; Brough D; Pathmanaban ON
Brain Commun; 2023; 5(4):fcad197. PubMed ID: 37680691
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of targeted therapy for vestibular schwannoma in patients with
Chiranth S; Langer SW; Poulsen HS; Urup T
Neurooncol Adv; 2023; 5(1):vdad099. PubMed ID: 37706198
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
Webb MJ; Neth BJ; Webb LM; Van Gompel JJ; Link MJ; Neff BA; Carlson ML; Driscoll CL; Dornhoffer J; Ruff MW; Anderson KA; Kizilbash SH; Campian JL; Uhm JH; Lane JI; Benson JC; Blezek DJ; Mehta PM; Bathla G; Sener UT
Neurooncol Adv; 2023; 5(1):vdad123. PubMed ID: 37841698
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Goutagny S; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis.
Tamura R; Yamanobe Y; Fujioka M; Morimoto Y; Fukumura M; Nakaya M; Oishi Y; Sato M; Ueda R; Fujiwara H; Hikichi T; Noji S; Oishi N; Ozawa H; Ogawa K; Kawakami Y; Ohira T; Yoshida K; Toda M
J Clin Oncol; 2024 May; ():JCO2302376. PubMed ID: 38776485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
